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Abstract
Background: The use of Doppler/Ultrasound is well documented in Cardiac, Vascular and Transplant surgery. It accurately detects
the flow of blood through a vessel, allowing for informed decision making regarding cannulation site, graft anastomosis and
assessment of graft patency. Trans-catheter Aortic Valve implantation (TAVI) has recently emerged as an effective treatment of
elderly or high risk patients with aortic stenosis. The transfemoral TAVI is the most frequently adopted strategy. However, many
patients referred for transfemoral TAVI present some degree of peripheral vascular disease and this is partially responsible for an
increased rate of vascular complications.
Methods: We present our experience in 50 patients who were referred for transfemoral TAVI at Oxford heart centre to confirm the
point of access for insertion of the femoral sheath and the quality of the femoral artery repair after direct repair.
Results: We present our experience with High risk cases with aortic stenosis. They have been accepted for transfemoral TAVI. In
order to confirm the point of access for insertion of the femoral sheath and Quality of repair, we used VeriQ system as standard
procedure.
Conclusion: The use of VeriQ system is safe and reproducible method to assess the Point of access for insertion of femoral sheath
and the quality of the femoral artery after direct repair in transfemoral TAVI.
Copyright © 2016, The Egyptian Society of Cardio-thoracic Surgery. Publishing services by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The use of Doppler/Ultrasound is well documented in Cardiac, Vascular and Transplant surgery [1]. The recent
Guidelines issued jointly in 2014 by the European Society of Cardiology (ESC) and the European Association of
Cardio-Thoracic Surgery (EACTS) recommended the use of Transit Time FlowMeasurement (TTFM) for verification
of graft patency [2]. The use of VeriQ system probe (Medistim®) to measure TTFM is supported by NICE (National* Corresponding author. Tel.: þ20 1002412099.
E-mail addresses: mohamedzeinah@gmail.com (M. Zeinah), amamo77@yahoo.com, amamo77@doctors.org.uk (A.M. Omran).
Peer review under responsibility of The Egyptian Society of Cardio-thoracic Surgery.
1 Tel.: þ44 7455257074 (mobile).
http://dx.doi.org/10.1016/j.jescts.2016.04.004
1110-578X/Copyright © 2016, The Egyptian Society of Cardio-thoracic Surgery. Publishing services by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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used routinely to assess graft quality during surgery [3].
2. Patients and method
From July 2014 till July 2015, data were retrospectively analysed at Oxford heart centre. We used VeriQ System in
consecutive 50 patients for transfemoral TAVI. The demographics of the patients were listed in Table 1.
These patients were subjected to observational study and analysis considering history taking, full clinical evalu-
ation and basic laboratory and imaging investigation according to guidelines preparation of patients undergoing TAVI.
All the patients underwent transfemoral TAVI after discussion in the MDT (Multidisciplinary team) as they have
been considered very high risk for conventional aortic valve replacement.
Patients referred for TAVI evaluation underwent interdisciplinary discussion within the local institutional Heart
Team consisting of invasive cardiologists, and cardiovascular surgeons. The indication for TAVI was based on pa-
tients' clinical history, clinical status, anatomical suitability, and geriatric assessment [4,5]. Patients underwent im-
plantation of the Edwards Sapien valve using the femoral access route as previously mentioned.
We introduced the use of VeriQ system before and after the procedure to check for the access and quality of repair
respectively.
3. Results
These results were subjected to statistical analysis.
The mean age was 85 ± 1.1. 30 patients were males.
The mean logistic EUROSCOREwas 20.8± 13.7, Most of the patients (87%) were in NYHA IV, and 9 patients had
prior CABG (Table 1).
The Ultrasound system was successful in detecting the femoral artery access for all the cases in this cohort. It was
safe with no complications detected in this group. Any patients with peripheral vascular disease were excluded from
this group. Other routes of TAVI (like transapical or transaortic) were used. Three cases had bleeding after introducing
the valve. The ultrasound system was effective in detecting the flow after the repair in all the cases.
4. Discussion
Currently, the only proven long-term effective treatment for patients with severe symptomatic aortic stenosis is
surgical valve replacement. However, many patients with severe symptomatic aortic stenosis remain untreated, often
because of the operative and perioperative risks associated with surgical repair. This group of 30%e60% of patients
with untreated aortic stenosis has a high mortality rate and needs to be served by the medical community [6]. The use
of a multidisciplinary team of cardiologists, cardiovascular surgeons, and supporting groups (for example, imagingTable 1
The patients' demographics.
Number of patients 50
Age 85 ± 1.1
Male 60%
EUROSCORE (logistic) 20.8 ± 13.7
Diabetes (insulin dependent) 62%
Pulmonary hypertension 42%
COPD 38%
Renal insufficiency 30%
History of stroke 22%
Porcelain aorta 12%
NYHA IV 84%
Ejection fraction (less than 40%) 38%
Prior CABG 18%
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TAVI to become the standard of care for inoperable patients with severe aortic stenosis. The available results indicate
that TAVI is an acceptable alternative to surgery in selected high-risk patients [6]. Future randomized studies should
focus on lower-risk patients who are candidates for operation [6].
Vascular-access complications associated with TAVI are expected to decrease as the design and performance of
new devices improve [6]. A major complication of the TAVI procedure is stroke; common causes include balloon
valvuloplasty, the passage of stiff catheters through an often-calcified aortic arch, the positioning and implantation of
the valve itself, and postdilation (if used) [6]. In a recent study, the incidence of stroke was lower than in previous
reports, probably because of the use of more flexible and smaller delivery systems [6]. Embolization-protection
devices and deflectors that can redirect emboli from the arch downstream are being developed and evaluated, but
no data support the clinical benefit of these devices [6].
The clinical durability of the valves used for TAVI is unknown [6]. In preclinical fatigue tests, the transcatheter
valves have shown the same excellent performance as standard biological valves; this applies both to the leaflets and toFig. 1. Coloured Doppler demonstrating blood flow through femoral artery after repair.
Fig. 2. The VeriQ machine.
Fig. 3. The VeriQ machine probe used.
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[6]. Long-term follow-up data are of course lacking.
Finally, another controversial issue is the use of TAVI in a younger, lower-risk population. In many centres, TAVI
has become a routine procedure, and the results of recent trials show improved outcomes and safety of the approach
[7]. However, the incidence of paravalvular leak and stroke, and the unknown durability factor are lingering concerns.
Vascular complications still remain a major drawback in percutaneous TAVI [7].
The use of VeriQ system may represent a useful tool to select the optimal vascular access during femoral can-
nulation, ensuring a safe and effective repair after the procedure.
The VeriQ system probe was used to confirm the point of access for insertion of the femoral sheath and the quality
of the femoral artery repair after direct repair (Fig. 1).
We assessed the quality of our femoral artery closures and the unobstructed patency of the femoral artery in a
timely and consistent manner that does not expose the patient to further contrast administration and radiation.
The VeriQ system can provide clear, printed documentation of blood flow, which can also be measured if needed,
by using the specialist Doppler flow probe (Figs. 2 and 3).5. Conclusion
The use of VeriQ system is safe and reproducible method to assess the Point of access for insertion of femoral
sheath and the quality of the femoral artery after direct repair in transfemoral TAVI.Conflict of interest
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